|
|
Post by mango on Oct 5, 2018 17:07:34 GMT -5
|
|
|
|
Post by mango on Oct 26, 2018 16:40:51 GMT -5
|
|
|
|
Post by mannmade on Oct 26, 2018 17:14:23 GMT -5
Oddly I believe Anders Boss was the senior medical officer at Sanofi working directly on Afrezza during the Sanofi partnership.
|
|
|
|
Post by mango on Nov 2, 2018 10:34:45 GMT -5
New MannKind Granted Patent 10/30/2018 Catalysis of diketopiperazine synthesisAbstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide. Type: Grant Filed: September 7, 2017 Date of Patent: October 30, 2018 Assignee: MannKind Corporation Inventors: John J. Stevenson, Destardi Moye-Sherman patents.justia.com/patent/10112910 |
|
|
|
Post by mango on Nov 8, 2018 12:31:58 GMT -5
Application Date:06.05.2013 Publication Date:25.10.2018 Applicants:MANNKIND CORPORATION Inventors:SMUTNEY, Chad, C OLIDORO, John, M.; KINSEY, P., Spencer; BRYANT, Anthony; SAHI, Carl, R.; ADAMO, Benoit; OVERFIELD, Dennis; MCLEAN, Scott; ( HE, Tom; MANN, Alfred; Title: (ID) INHALER SERBUK KERING DAN SISTEM PENGANTARAN OBAT • Indonesian translation: INHALER OF DRY POWDER AND DRUG EXCHANGE SYSTEM Abstract: (ID) Suatu inhaler serbuk kering, kartrid, dan sistem pengantaran obat pulmonarl diberikan. inhaler serbuk kering dapat diberikan dengan atau tanpa kartrid dosis unit untuk digunakan dengan inhaler tersebut. Inhaler dan/atau kartrid dapat dilengkapi dengan suatu formulasi pengantaran obat yang terdiri dari, sebagai contoh, diketopiperazina dan bahan aktif, yang meliputi, peptida-peptida dan protein-protein seperti insulin dan peptida mirip glukagon 1 untuk pengobatan diabetes dan/atau obesitas. Inhaler serbuk kering adalah ringkas,' dapat diberikan dalam bermacam bentuk dan ukuran,warna, dan terdiri dari rumahan, bagian mulut, daerah penempatan kartrid, dan mekanisme untuk pembukaan dan penutupan kartrid obat. Alat tersebut mudah untuk dibuat, memberikan suatu dosis unit tunggal yang diukur awal yang relatif mudah untuk digunakan, dan dapat dipakai ulang atau sekali pakai. • Indonesian translation: A dry powder inhaler, cartridge, and pulmonarl drug delivery system are provided. Dry powder inhalers can be supplied with or without a unit dose cartridge for use with the inhaler. Inhalers and / or cartridges can be equipped with a drug delivery formulation consisting of, for example, diketopiperazina and active ingredients, which include, peptides and proteins such as insulin and glucagon 1-like peptides for the treatment of diabetes and / or obesity. Dry powder inhalers are compact, 'can be given in various shapes and sizes, colors, and consist of housing, mouth parts, cartridge placement areas, and mechanisms for opening and closing drug cartridges. The tool is easy to make, giving a single unit dose measured early which is relatively easy to use, and can be reused or disposable. patentscope.wipo.int/search/en/detail.jsf?docId=ID232584451&recNum=2&office=&queryString=FP%3A%28MannKind%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=1121
|
|
|
|
Post by mango on Nov 22, 2018 20:33:51 GMT -5
Three New Granted MannKind Patents Published 11/20/2018 Diketopiperazine salts for drug delivery and related methodsAbstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization. Type: Grant Filed: June 9, 2017 Date of Patent: November 20, 2018 Assignee: MannKind Corporation Inventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson patents.justia.com/patent/10130685High capacity diketopiperazine microparticles and methodsAbstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation. Type: Grant Filed: May 11, 2016 Date of Patent: November 20, 2018 Assignee: MannKind Corporation Inventors: Marshall Grant, Paul Menkin, Grayson W. Stowell patents.justia.com/patent/10130709Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentAbstract:Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery. Type: Grant Filed: December 16, 2015 Date of Patent: November 20, 2018 Assignee: MannKind Corporation Inventors: Bryan R. Wilson, Marshall Grant patents.justia.com/patent/10130581 |
|
|
|
Post by sr71 on Nov 23, 2018 10:26:22 GMT -5
Three New Granted MannKind Patents Published 11/20/2018 Diketopiperazine salts for drug delivery and related methodsAbstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization. Type: Grant Filed: June 9, 2017 Date of Patent: November 20, 2018 Assignee: MannKind Corporation Inventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson patents.justia.com/patent/10130685High capacity diketopiperazine microparticles and methodsAbstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation. Type: Grant Filed: May 11, 2016 Date of Patent: November 20, 2018 Assignee: MannKind Corporation Inventors: Marshall Grant, Paul Menkin, Grayson W. Stowell patents.justia.com/patent/10130709Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentAbstract:Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery. Type: Grant Filed: December 16, 2015 Date of Patent: November 20, 2018 Assignee: MannKind Corporation Inventors: Bryan R. Wilson, Marshall Grant patents.justia.com/patent/10130581Mango - It's interesting that the first patent you listed shows Andrea Leone-Bay as the lead inventor with rights assigned to Mannkind. By my reckoning, I believe that the June 9, 2017 patent filing date was well after Andrea had left Mannkind to become an employee of RLS. Maybe she returned to Mannkind? Or, perhaps there is an agreement between Mannkind, RLS, and Andrea regarding patent protections/ownership for Mannkind? |
|
|
|
Post by agedhippie on Nov 23, 2018 14:10:21 GMT -5
Mango - It's interesting that the first patent you listed shows Andrea Leone-Bay as the lead inventor with rights assigned to Mannkind. By my reckoning, I believe that the June 9, 2017 patent filing date was well after Andrea had left Mannkind to become an employee of RLS. Maybe she returned to Mannkind? Or, perhaps there is an agreement between Mannkind, RLS, and Andrea regarding patent protections/ownership for Mannkind? I would not read to much into names on patents with companies. Since the people named on the patent will have assigned their rights to the patent in their contracts the names are really just there for bragging rights, certainly that's how it has always been with me. Exactly when a patent is filed depends on workload, importance, etc. as a lot of them are filed for deterrence rather than protection. When someone comes knocking claiming a patent infringement you want a pool of patents to threaten them with in turn. |
|
|
|
Post by mango on Dec 4, 2018 12:03:15 GMT -5
New International MannKind Patent Published 11/29/2018 APPARATUS AND METHOD FOR CRYOGRANULATING A PHARMACEUTICAL COMPOSITIONAbstract: Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing. Type: Application Filed: August 1, 2018 Publication date: November 29, 2018 Applicant: MannKind Corporation Inventors: Edwin Amoro, Karel Vanackere, Michael A. White patentscope.wipo.int/search/en/detail.jsf?docId=US234195871&recNum=1&office=&queryString=FP%3A%28MannKind%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=1128 |
|
|
|
Post by mango on Dec 11, 2018 9:32:37 GMT -5
New MannKind Granted Patent Published 12/10/2018 Method of drug formulationAbstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.
Type: Grant
Filed: August 10, 2016
Date of Patent: December 4, 2018
Assignee: MannKind Corporation
Inventors: Mark Hokenson, Keith A. Oberg
Example 6
Effects on Cyclosporin A Adsorption to FDKP ParticlesExample 7
Pulmonary Insufflation of Cyclosporin A/DKP ParticlesCyclosporin is an immunosuppressant. patents.justia.com/patent/10143655#claimsNew International MannKind Patent Published 12/5/2018 DRY POWDER INHALERApplication date: 27.01.2017 Publication date: 05.12.2018 Applicants:MANNKIND CORP Inventors:KINSEY P SPENCER LAURENZI BRENDAN SMUTNEY CHAD C ADAMO BENOIT GUARNERI JOSEP Title:(FR) INHALATEUR À POUDRE SÈCH (EN) DRY POWDER INHALER (DE) TROCKENPULVERINHALATO Abstract:(FR) L'invention concerne un inhalateur à poudre sèche comprenant des cartouches remplaçables contenant une poudre sèche pour une administration locale ou systémique à travers le tractus pulmonaire et les poumons. Les inhalateurs sont utilisés avec des poudres sèches pouvant être inhalées, comprenant des formulations de médicament contenant des agents actifs pour une administration locale ou systémique et pour le traitement de maladies telles que l'hypertension pulmonaire, une maladie cardiovasculaire, l'anaphylaxie, le diabète, l'obésité, le cancer et d'autres maladies, ou des symptômes associés à ces dernières et d'autres maladies, tels que la nausée, les vomissements, une douleur et une inflammation. (EN) A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation. patentscope.wipo.int/search/en/detail.jsf?docId=EP234471487&recNum=1&office=&queryString=FP%3A%28MannKind%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=1130 |
|
|
|
Post by Clement on Dec 11, 2018 10:12:53 GMT -5
Thanks, Mango,
I'm thinking Cyclosporin A -> lung transplant -> UTHR. Hmmm.
|
|
|
|
Post by mango on Jan 2, 2019 12:49:08 GMT -5
New Joint MannKind & TechnoVax Granted Patent 12/25/2018 Inhalable vaccine compositions and methodsAbstract: Dry powder inhalable compositions and methods for using and making the compositions are disclosed for vaccinating a subject against disease. In particular, the compositions are inhalable dry powders useful for preventing and/or treating diseases caused by microorganisms, for example, microorganisms such as viral or bacterial pathogens, including, the influenza virus. In particular, the method comprises the administration of an inhalable composition comprising virus-like particles and/or specific protein/s or antigenic peptides, peptide fragments and/or derivatives thereof using a dry powder drug delivery system. Type: Grant Filed: October 25, 2013 Date of Patent: December 25, 2018 Assignees: MannKind Corporation, Technovax, Inc. Inventors: Chad C. Smutney, Andrea Leone-Bay, Jose M. Galarza, Hector Munoz, George R. Martin, Marshall L. Grant patents.justia.com/patent/10159644 |
|
|
|
Post by Clement on Jan 2, 2019 13:24:50 GMT -5
New Joint MannKind & TechnoVax Granted Patent 12/25/2018 Inhalable vaccine compositions and methodsAbstract: Dry powder inhalable compositions and methods for using and making the compositions are disclosed for vaccinating a subject against disease. In particular, the compositions are inhalable dry powders useful for preventing and/or treating diseases caused by microorganisms, for example, microorganisms such as viral or bacterial pathogens, including, the influenza virus. In particular, the method comprises the administration of an inhalable composition comprising virus-like particles and/or specific protein/s or antigenic peptides, peptide fragments and/or derivatives thereof using a dry powder drug delivery system. Type: Grant Filed: October 25, 2013 Date of Patent: December 25, 2018 Assignees: MannKind Corporation, Technovax, Inc. Inventors: Chad C. Smutney, Andrea Leone-Bay, Jose M. Galarza, Hector Munoz, George R. Martin, Marshall L. Grant patents.justia.com/patent/10159644"Inhaled Powder" Vaccines -- on Technovax website technovax.com/inhaled-powder-vaccines/ |
|
|
|
Post by #NoMoreNeedles on Jan 2, 2019 13:31:19 GMT -5
Last website update: 2013!?
|
|
|
|
Post by goyocafe on Jan 2, 2019 13:38:05 GMT -5
Last website update: 2013!? Par for the course. |
|
